Although there has been little research on USP7 and RCC, further development and clinical trials of USP7 inhibitors in combination with PD-L1/PD-1 checkpoint inhibitors have significant potential to offer new valuable avenues for immunotherapy in RCC. This evidence concerns the gene PDCD1 and renal cell carcinoma.